New Anticoagulant Therapy

Tuesday, April 19, 2011 at 3:02:13 PM

A new anticoagulant therapy was recently approved for UHS formulary by the Pharmacy and Therapeutics Committee. Dabigatran (commercially sold as PradaxaŽ) was approved by the FDA as an oral anticoagulant to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF). Dabigatran is a direct thrombin (factor IIa) inhibitor. The RE-LY trial suggests that dabigatran offers similar efficacy in stroke prevention as warfarin (CoumadinŽ). Dabigatran has a quick onset of action where blood levels peak in 1-2 hours and a steady-state in 2-3 days. It requires twice daily dosing to maintain steady blood levels. Dabigatran does not require laboratory monitoring, such as INR; however, there is no antidote for reversing the effect of dabigatran. Therapy should be stopped if a patient has an active pathological bleeding. For questions, please contact the Pharmacy Department.

Return To Home Page